The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Featured:
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke with Lori Muffly, Stanford Medicine, Stanford, US. We asked about the geographical barriers to accessing specialty cancer care among adolescents and young adults with ALL.
What are the geographical barriers to accessing specialty cancer care among young adults with ALL?
Muffly discusses the geographical barriers to receiving specialty cancer care among young adolescent patients with ALL. Research was conducted to quantify the distance between patient residences and treatment centers, such as National Cancer Institute designated cancer centers or Children’s Oncology Group sites. She then discusses the results, highlighting long travel times as a significant geographical barrier to accessing care across the U.S. and concluding that more networks and centers are needed.
Your opinion matters
On average, how many patients with T-cell acute lymphoblastic leukemia do you see in a year?